Abstract
Acinetobacter baumannii has been defined by the World Health Organization as a critical pathogen in severely ill patients admitted to intensive care units (ICUs) and neonatal ICUs (NICUs) worldwide. 1 This pathogen is known as an opportunistic pathogen that can cause serious infections to hospitalized patients, such as blood stream infections, chest infections, wound infections, and ventilator-associated pneumonia. 2 A. baumannii can survive in the environment, 3 and several risk factors are attributed to the colonization and infection of A. baumannii, these factors include underlying diseases, ICU stay, long hospitalization, use of broad spectrum antibiotics, catheterization, and mechanical ventilation. 1 Antimicrobial drug resistance in A. baumannii has been reported worldwide, particularly carbapenem-resistant strains, which considerably limits the range of therapeutic alternatives available due to the different mechanisms used by this pathogen to resist antibiotics.